Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment
about
Effects of anti-tumor necrosis factor α agents on boneBone remodelling markers in rheumatoid arthritis.Novel treatments for cancer cachexia.IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylosing spondylitis patients undergoing anti-TNF-alpha therapyImpact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis.Changing shape of disease: nonalcoholic fatty liver disease in Crohn's disease-a case series and review of the literatureBone mass in axial spondyloarthritis: A literature review.Cardiovascular risk in patients with psoriatic arthritis.Is there a relation between pre-sarcopenia, sarcopenia, cachexia and osteoporosis in patients with ankylosing spondylitis?A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab.Tumour necrosis factor inhibitors in ankylosing spondylitis.Adiposity and tendinopathy.Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFalpha therapy.Influence of ustekinumab on body weight of patients with psoriasis: an initial report.Anti-cytokine strategies for the treatment of cancer-related anorexia and cachexia.Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis.Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease.Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies.The Impact of Conventional and Biological Disease Modifying Antirheumatic Drugs on Bone Biology. Rheumatoid Arthritis as a Case Study.TNF and IL-18 cytokines may regulate liver fat storage under homeostasis conditions.The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature.Impact of 24 months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study.Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study.Bone loss in patients with early inflammatory back pain suggestive of spondyloarthritis: results from the prospective DESIR cohort.Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study.Bone oedema on MRI is highly associated with low bone mineral density in patients with early inflammatory back pain: results from the DESIR cohort.Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study.Association between bone mineral density and C-reactive protein in a large population-based sample.The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.Anti-tumour necrosis factor-α treatment and weight gain in psoriasis: the 'pudgy blanching' conundrum.Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.Body weight increment in patients treated with infliximab for plaque psoriasis.Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis.Effects of tumor necrosis factor α on leptin-sensitive intestinal vagal mechanoreceptors in the cat.Inflammatory diseases and bone fragility.Psoriasis improvement after gastric bandage in a patient partial responder to infliximab.Reduced Appendicular Lean Body Mass, Muscle Strength, and Size of Type II Muscle Fibers in Patients with Spondyloarthritis versus Healthy Controls: A Cross-Sectional Study.Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulin‐like growth factor
P2860
Q26851274-B2F43BE4-7E19-482A-A890-99F48D91EC3DQ33563068-38DBAC7B-64D7-4B15-A918-88D9396ED77FQ34005616-0909A319-DA27-4333-93D6-D073D21DB37BQ34250990-14BF1716-7283-465A-A54A-F27216110A1DQ34631127-8E0E868B-EB00-40F6-BE1E-298CECC29DB1Q35109416-3C1B9227-B39C-4EFA-BBC6-1D39E455DB09Q35188767-40122425-6A77-4152-AD3F-DD9113F52BD8Q35974962-67467C03-26FA-4A47-8F40-ED9C0DF3A8FCQ36073054-DC4735AC-47E8-4A46-BC9D-61A1370EB27AQ36392269-63C40F53-654B-49C4-B06D-B5C69E40DDC1Q37142118-0DDEA70D-7313-4D90-9F5E-7545688B2722Q37209851-EC2ACE6C-AC51-4D43-8773-BB222420FC4CQ37307876-139E9F96-C640-46C6-A07A-DA955B2BAB0EQ37634328-9E84D90F-3C78-4261-BCC0-5E2BF361BBC5Q37769250-D4B17488-6C68-437E-9549-751C17A73333Q37801555-E5BB223C-A778-4F00-9E7D-6F3844C717F7Q38041419-6F5877EA-05BC-4C3F-A448-BC6650E55CC8Q38099248-1BADA686-D160-47AE-BC48-62C2CA56FB51Q38831693-917F06C9-8902-49A5-8DAE-678121E3BC4BQ39174269-9FEF0B75-0EF5-423C-B364-FE8AEA06BD9DQ39218034-69A7C6E9-BDF9-463E-94D7-A1E42AEB48D4Q39861020-59E3DC88-AB69-4AAD-85D0-00D948DCD418Q40405924-5A1B3D7A-7FBB-4C07-A586-CE9DA2C95A0DQ41371671-E8EBBA5B-19A5-47E4-A3D1-9AA3CE9AA9CDQ45077865-48DA5879-99B0-4C5C-886C-33187EDB1670Q45299337-FD731C44-707F-4302-847B-9F8F14D0BF18Q45761302-38BC5C97-1859-41F3-8855-0CA947A36A64Q46930094-82270227-FD87-440F-B488-D89F19CFEF74Q47177526-B553875C-5D28-482A-A07C-6DFA96EBC1CFQ47239360-F0BC08F6-C7AC-4DF7-A320-590FC4AAF297Q47261263-8D35351F-EAA4-4546-893D-EE4D399066B4Q47308544-C02E611F-5157-4CC2-BC83-FBDCBE2FA801Q47349081-047636ED-01CB-414D-B95B-8A6993A53C43Q47962128-8F5C9801-61F5-42A8-B414-7465AA22DC0CQ47975714-F36E4843-CB6F-4166-9B3C-AFD105956CE8Q48162210-DDCF0B4E-82BE-42FF-9B50-4B9EEF479898Q53021234-18410791-9034-4239-BE3A-39FA16517A6EQ58329736-EB02F01D-7483-45DE-A778-97DF98882F0C
P2860
Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Body weight, body composition, ...... rosis factor {alpha} treatment
@ast
Body weight, body composition, ...... rosis factor {alpha} treatment
@en
type
label
Body weight, body composition, ...... rosis factor {alpha} treatment
@ast
Body weight, body composition, ...... rosis factor {alpha} treatment
@en
prefLabel
Body weight, body composition, ...... rosis factor {alpha} treatment
@ast
Body weight, body composition, ...... rosis factor {alpha} treatment
@en
P2093
P2860
P356
P1476
Body weight, body composition, ...... rosis factor {alpha} treatment
@en
P2093
P2860
P304
P356
10.1136/ARD.2004.028670
P407
P50
P577
2005-01-07T00:00:00Z